 BetterLife Pharma Inc CSE:BETR OTCQB:BETRF FRA:NPAU has announced that its wholly-owned subsidiary Altum Pharmaceuticals has entered into a Letter of Intent with Pontificia Universidad Católica de Chile to conduct a randomized, placebo-controlled trial in COVID-19 patients testing Altums proprietary inhaled interferon alpha-2b product AP-003. The IN2COVID trial is projected to start in the second quarter of this year and be completed by the end of the 3Q, the company said in a statement Thursday. 